LT3004166T - Alergeno atžvilgiu specifinės imunoterapijos sustiprinimo būdai, įvedant il-4r inhibitorių - Google Patents

Alergeno atžvilgiu specifinės imunoterapijos sustiprinimo būdai, įvedant il-4r inhibitorių

Info

Publication number
LT3004166T
LT3004166T LTEP14733922.0T LT14733922T LT3004166T LT 3004166 T LT3004166 T LT 3004166T LT 14733922 T LT14733922 T LT 14733922T LT 3004166 T LT3004166 T LT 3004166T
Authority
LT
Lithuania
Prior art keywords
allergen
inhibitor
introducing
context
methods
Prior art date
Application number
LTEP14733922.0T
Other languages
English (en)
Lithuanian (lt)
Inventor
Neil Stahl
Jamie ORENGO
Andrew Murphy
Namita GANDHI
Neil Graham
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT3004166T publication Critical patent/LT3004166T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
LTEP14733922.0T 2013-06-04 2014-06-03 Alergeno atžvilgiu specifinės imunoterapijos sustiprinimo būdai, įvedant il-4r inhibitorių LT3004166T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361830919P 2013-06-04 2013-06-04
PCT/US2014/040695 WO2014197470A1 (en) 2013-06-04 2014-06-03 Mehods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

Publications (1)

Publication Number Publication Date
LT3004166T true LT3004166T (lt) 2019-12-27

Family

ID=51023185

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14733922.0T LT3004166T (lt) 2013-06-04 2014-06-03 Alergeno atžvilgiu specifinės imunoterapijos sustiprinimo būdai, įvedant il-4r inhibitorių

Country Status (25)

Country Link
US (5) US10392439B2 (enExample)
EP (2) EP3617233A1 (enExample)
JP (6) JP6499167B2 (enExample)
KR (3) KR102355114B1 (enExample)
CN (3) CN117982639A (enExample)
AU (3) AU2014275094C1 (enExample)
CA (1) CA2914203C (enExample)
CY (1) CY1124095T1 (enExample)
DK (1) DK3004166T3 (enExample)
ES (1) ES2767080T3 (enExample)
HR (1) HRP20200185T1 (enExample)
HU (1) HUE048655T2 (enExample)
IL (3) IL273678B2 (enExample)
LT (1) LT3004166T (enExample)
MX (2) MX384112B (enExample)
NZ (1) NZ630183A (enExample)
PL (1) PL3004166T3 (enExample)
PT (1) PT3004166T (enExample)
RS (1) RS59883B1 (enExample)
RU (1) RU2679920C2 (enExample)
SG (3) SG10201913835XA (enExample)
SI (1) SI3004166T1 (enExample)
TW (3) TWI755763B (enExample)
WO (1) WO2014197470A1 (enExample)
ZA (1) ZA201508174B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
RS59354B1 (sr) 2013-06-21 2019-10-31 Sanofi Biotechnology Postupci lečenja nosne polipoze davanjem il-4r antagonista
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
EP3954710A3 (en) 2015-04-02 2022-07-20 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
ES3014160T3 (en) * 2015-12-18 2025-04-21 Intervet Int Bv Caninized human antibodies to human and canine il-4r alpha
EP3416685B1 (en) 2016-02-19 2024-06-26 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
AU2017228329B2 (en) * 2016-03-01 2021-03-11 Corcept Therapeutics, Inc. The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
AU2017312785B2 (en) 2016-08-16 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
KR102872485B1 (ko) * 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
WO2018053244A1 (en) * 2016-09-16 2018-03-22 Dyax Corp. Protein biomarkers for diseases associated with the contact activation system
KR102759512B1 (ko) 2016-10-25 2025-02-03 리제너론 파아마슈티컬스, 인크. 크로마토그래피 데이터 분석을 위한 방법 및 시스템
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
US11034768B2 (en) 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
CN117405806A (zh) * 2017-12-13 2024-01-16 里珍纳龙药品有限公司 管理层析柱床支架的装置和系统及相关方法
WO2019148405A1 (zh) * 2018-02-01 2019-08-08 北京凯因科技股份有限公司 IL-4Rα抗体及其用途
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
CN112533675A (zh) * 2018-04-25 2021-03-19 基尼克萨制药有限公司 通过递送抗OSMRβ抗体治疗皮肤疾病或病症
TWI903214B (zh) 2018-05-02 2025-11-01 美商里珍納龍藥品有限公司 用於評估生化過濾器的適合性的方法
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
TWI919355B (zh) 2018-07-02 2026-03-21 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
MX2021000239A (es) * 2018-07-10 2021-03-25 Regeneron Pharma Modificacion de moleculas de union para minimizar interacciones preexistentes.
JP2022500037A (ja) * 2018-09-14 2022-01-04 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための抗ｉｌ４受容体抗体
KR102330596B1 (ko) * 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CN111494626B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
SG11202107007VA (en) * 2018-12-27 2021-07-29 Akeso Biopharma Inc Antibody against human il-4ra and use thereof
RU2700788C1 (ru) * 2019-01-17 2019-09-23 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ оценки эффективности проведения аллерген-специфической иммунотерапии при аллергическом рините
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
KR20210143246A (ko) * 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
US11504426B2 (en) * 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
WO2021102186A1 (en) * 2019-11-20 2021-05-27 Aimmune Therapeutics, Inc. Methods and systems for managing distribution and treatment of a food allergy oral immunotherapy drug
CA3161037A1 (en) 2019-12-09 2021-06-17 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
BR112022011797A2 (pt) 2019-12-20 2022-08-30 Intervet Int Bv Anticorpos contra receptor alfa de interleucina-4 canino
AU2021214938B2 (en) 2020-01-29 2024-02-08 Corcept Therapeutics Incorporated Treatment of adrenocortical carcinoma with selective glucocorticoid receptor modulators (SGRMs) and antibody checkpoint inhibitors
CN113527485B (zh) * 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
KR102468170B1 (ko) * 2020-07-17 2022-11-17 (주)지아이이노베이션 ＩｇＥ Ｆｃ 수용체 알파서브유닛의 세포외 도메인 및 항-IL-4R 항체를 포함하는 융합단백질 및 이의 용도
US20220220211A1 (en) * 2021-01-08 2022-07-14 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
AU2022316939A1 (en) * 2021-07-26 2024-03-07 Regeneron Pharmaceuticals, Inc. Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
CN115960236B (zh) * 2023-01-05 2024-08-06 江苏荃信生物医药股份有限公司 一种定量检测血清中抗人白介素4受体α单克隆抗体含量的酶联免疫分析方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
KR20260105275A (ko) * 2024-12-26 2026-07-06 주식회사 종근당 항-hIL-4Rα 항체를 위한 안정화된 액상 조성물

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
EP0668774A1 (en) 1991-05-03 1995-08-30 Seragen, Inc. Interleukin receptor targeted molecules for treatment of inflammatory arthritis
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US6598603B1 (en) 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
JP2003524602A (ja) 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ATE372764T1 (de) 2000-07-26 2007-09-15 Hououdou Co Ltd Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
WO2002092125A1 (en) 2001-05-11 2002-11-21 Novartis Ag Compositions for use in treating ige-associated disorders
CA2447795A1 (en) 2001-05-23 2002-11-28 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
EP2990394A1 (en) 2001-11-30 2016-03-02 Biogen MA Inc. Antibodies against monocyte chemotactic proteins
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
WO2004070010A2 (en) 2003-02-01 2004-08-19 Tanox, Inc. A method for generating high affinity antibodies
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
WO2005085284A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 sepecific polypetides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
WO2006083390A2 (en) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PL2132230T3 (pl) 2007-03-22 2014-09-30 Genentech Inc Apoptotyczne przeciwciała anty-IgE wiążące IgE związaną z błoną
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
CA2748712A1 (en) 2008-12-01 2010-06-10 Children's Hospital Medical Center Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
EP2414520A2 (en) 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
CN102596237A (zh) 2009-09-07 2012-07-18 Dbv技术公司 治疗嗜酸细胞性食管炎的方法
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
US20120164080A1 (en) 2010-06-24 2012-06-28 Meritage Pharma, Inc. Methods of treatment for esophageal inflammation
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
US20130324435A1 (en) 2011-01-06 2013-12-05 Children's Hospital Medical Center Esophageal cytokine expression profiles in eosinophilic esophagitis
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
US9928344B2 (en) 2011-06-21 2018-03-27 Children's Hospital Medical Center Diagnostic methods of eosinophilic esophagitis
CN103974706A (zh) 2011-10-06 2014-08-06 N·V·努特里奇亚 嗜酸细胞性食管炎的治疗
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CN118286417A (zh) * 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
RS59354B1 (sr) 2013-06-21 2019-10-31 Sanofi Biotechnology Postupci lečenja nosne polipoze davanjem il-4r antagonista
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
EP3416685B1 (en) 2016-02-19 2024-06-26 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
KR102872485B1 (ko) 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
RU2759630C2 (ru) 2016-09-22 2021-11-16 Ридженерон Фармасьютикалз, Инк. Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
US11034768B2 (en) 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
CA3161037A1 (en) 2019-12-09 2021-06-17 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
JP7862322B2 (ja) 2020-05-22 2026-05-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法

Also Published As

Publication number Publication date
HUE048655T2 (hu) 2020-08-28
TWI633891B (zh) 2018-09-01
US11485788B2 (en) 2022-11-01
WO2014197470A1 (en) 2014-12-11
IL273678A (en) 2020-05-31
US10392439B2 (en) 2019-08-27
JP2025011257A (ja) 2025-01-23
IL312710A (en) 2024-07-01
TW202038999A (zh) 2020-11-01
JP7061163B2 (ja) 2022-04-27
CN105377894A (zh) 2016-03-02
AU2014275094A1 (en) 2015-12-17
PL3004166T3 (pl) 2020-06-01
CA2914203C (en) 2024-04-16
CN117982639A (zh) 2024-05-07
DK3004166T3 (da) 2020-01-06
JP2019112440A (ja) 2019-07-11
RU2015156628A (ru) 2017-07-14
PT3004166T (pt) 2020-01-14
ES2767080T3 (es) 2020-06-16
CY1124095T1 (el) 2022-03-24
IL312710B2 (en) 2026-08-01
MX2021002173A (es) 2021-04-28
KR102492826B1 (ko) 2023-01-30
JP2022101613A (ja) 2022-07-06
IL273678B2 (en) 2024-10-01
JP2016521713A (ja) 2016-07-25
TWI755763B (zh) 2022-02-21
CA2914203A1 (en) 2014-12-11
AU2021229250A1 (en) 2021-10-07
JP6754857B2 (ja) 2020-09-16
JP2020193218A (ja) 2020-12-03
AU2019204577A1 (en) 2019-07-18
US20200299393A1 (en) 2020-09-24
EP3004166A1 (en) 2016-04-13
KR102355114B1 (ko) 2022-01-27
SI3004166T1 (sl) 2020-02-28
HK1216898A1 (en) 2016-12-09
MX2015016473A (es) 2016-03-03
SG10201709670XA (en) 2018-01-30
TWI697334B (zh) 2020-07-01
IL312710B1 (en) 2026-04-01
RU2019103601A (ru) 2019-03-12
AU2019204577B2 (en) 2021-06-24
AU2014275094B2 (en) 2019-03-28
JP7284313B2 (ja) 2023-05-30
NZ630183A (en) 2018-10-26
SG10201913835XA (en) 2020-03-30
US20140356372A1 (en) 2014-12-04
JP6499167B2 (ja) 2019-04-10
IL242456B (en) 2020-04-30
IL273678B1 (en) 2024-06-01
MX384112B (es) 2025-03-14
EP3004166B1 (en) 2019-11-20
RU2015156628A3 (enExample) 2018-05-30
TW201519905A (zh) 2015-06-01
ZA201508174B (en) 2017-09-27
KR20230017923A (ko) 2023-02-06
AU2014275094C1 (en) 2019-10-10
JP2023103389A (ja) 2023-07-26
EP3617233A1 (en) 2020-03-04
US10676530B2 (en) 2020-06-09
KR20220011810A (ko) 2022-01-28
US20230159647A1 (en) 2023-05-25
HRP20200185T1 (hr) 2020-05-01
SG11201509044QA (en) 2015-12-30
TW201906630A (zh) 2019-02-16
RS59883B1 (sr) 2020-03-31
KR20160014626A (ko) 2016-02-11
JP7575526B2 (ja) 2024-10-29
US20180094070A1 (en) 2018-04-05
AU2021229250B2 (en) 2024-11-14
KR102580468B1 (ko) 2023-09-21
CN118001391A (zh) 2024-05-10
US20180094069A1 (en) 2018-04-05
RU2679920C2 (ru) 2019-02-14
US10669341B2 (en) 2020-06-02

Similar Documents

Publication Publication Date Title
HUS2400016I1 (hu) FCRN elleni antitestek
IL289821B (en) Compositions and methods for immunotherapy
PL3004166T3 (pl) Sposoby ulepszania swoistej immunoterapii alergenowej przez podawanie inhibitora IL-4R
DK3406633T3 (da) Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf
IL245935A0 (en) Methods for RNA analysis
GB2499921B (en) Biophotonic compositions, kits and methods
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
IL246002A0 (en) Novel methods
HUE055044T2 (hu) MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények
SG11201506660RA (en) Methods, compositions, and kits for nucleic acid analysis
LT3074534T (lt) Būdai, skirti polinukleotido sekoskaitai
HUE053439T2 (hu) Sejtes immunterápiára szolgáló eljárás és készítmények
DK3083680T3 (da) Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse
GB201319161D0 (en) Multivalent antigen-binding protein molecules
IL285527A (en) Compositions and methods for immunotherapy
EP3065776A4 (en) Novel anti-claudin antibodies and methods of use
IL243311A0 (en) Novel antibody frameworks
PT3004163T (pt) Método para purificação de anticorpo
EP3080607A4 (en) Novel anti-dpep3 antibodies and methods of use
IL240753B (en) Methods for purifying antibodies
HUE042607T2 (hu) Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával
LT3520811T (lt) Būdai, skirti atsmatikų priverstinio iškvėpimo tūrio padidinimui naudojant benralizumabą
DK3047028T5 (da) Fermenteringsfremgangsmåde
IL243790A0 (en) Devices, kits and methods of connection
TH1301005529B (th) วิธีการผลิตวัสดุมีพื้นฐานคีโรซีนและวัสดุมีพื้นฐานคีโรซีน